Ultrasound-guided percutaneous radiofrequency ablation versus microwave ablation for patients with b

• 作 者: Wenwen YUE Huixiong XU Shurong WANG Feng LU
• 机 构: Department of Ultrasound in Medicine,Tenth Affiliated People's Hospital of Tongji University,Shangh
• 出 处: 第三届全国暨国际超声分子影像及生物效应和治疗学术会议
• 发表日期: 2016年9期

　　Objective To compare the efficacy and safety of ultrasound-guided percutaneous microwave ablation (MWA) and radiofrequency ablation (RFA) for treatment of benign thyroid nodules (BTNs).Materials and Methods From June 2012 to March 2015,235 patients with BTNs were studied retrospectively, including 68 patients treated with RFA and 167 patients treated with MWA.A 1∶1 RFA-MWA matched group was created by using propensity score matching based on variables of sex,age,nodule composition, macrocalcification, nodule diameter, volume,follow-up period, symptoms and cosmetic score.Nodule volume, thyroid function and clinical symptoms were evaluated before treatment and at 1,3,6 and 1 2 months after the treatment to monitor changes in the volume, adverse effect and complications.Primary end points were the volume reduction ratio (VRR) at 1-, 3-, 6-and 12-month.Secondary end points consisted of therapeutic success rate,improvement of symptoms and cosmetic scores,major complications, ablation time and cost.Results Between the propensity-matched RFA and MWA groups,no significant differences were found in all nodule volume-related endpoints at 12 months after treatments (VRR:89.1% vs.87.1% ,P=0.154;Symptom score:0.7 versus 0.8, P=0.797; Cosmetic score: 1.5 vs.1.4, P=0.775.Therapeutic success rates : 100% vs.98.5%, P>0.99).No major complications occurred in either group (P>0.99).However, the MWA group was better than the RFA group in shortening treatment time (190s vs.250s,P<0.001) and lowering costs($1960.5 vs.$ 2640.6 ,P<0.001).Conclusion MWA and RFA are both effective and safe methods in treating BTNs.With well-matched treatment groups and consistent ablation procedure design,our results demonstrated that MWA may be a better and more appropriate treatment modality for BTNs,which has comparable therapeutic efficacy to,but is time saving and less expensive than, RFA.